Takahashi N, et al. - The safety and efficacy of intraperitoneal (IP) administration of paclitaxel for the treatment of peritoneal metastasis and the most frequent pattern of recurrence in gastric cancer after D2 gastrectomy were determined. It was determined that IP treatment did not confer notable overall or progression-free survival benefits. This treatment appeared to be correlated with particularly poor performance in individuals with residual disease, including positive peritoneal washing cytology (CY1) in the P0 population. Therefore, the superiority of IP paclitaxel over IV paclitaxel post-operatively to control advanced gastric cancer with a high risk of peritoneal recurrence was not shown.